Forbion — Full Portfolio

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)James Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVSVishwas Setia(Executive Officer)inChristopher A. Kroeger(President, Chief Executive Officer and Director)

Board seatNLNanna Lüneborg· per SEC Form D

Co-investorsAVAvego BioScience CapitalPIPivotal Life SciencesNONovo Holdings

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

GWGarrett Winslow(Executive Officer)inLFLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsACAccess BiotechnologyVIViking GlobalANAndreessen HorowitzBABAM ElevateBABay City CapitalCOCommodore Capital+8 more

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)HOHermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBIBioGeneration VenturesBIBioMedPartnersJEJeito CapitalPIPictet GroupASAsahi Kasei Corporate Venture CapitalSESeroba Life Sciences

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

DCDaniel Chung(Chief Medical Officer)inLBLance Baldo(Chief Executive Officer)inASAbraham Scaria(Chief Scientific Officer)in

Co-investorsADAdvent Life SciencesOXOxford Science EnterprisesTCTCG Crossover

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)SCScott Clarke(Chief Executive Officer)inPGPeter Garcia(Chief Financial Officer)SRSujata Rao(Chief Medical Officer)inSRStefan Ries(Chief Scientific Officer and Head of Munich Site)inAGAndrea Goddard(Chief Technical Officer)in

Co-investorsJEJeito CapitalBIBioqube VenturesBABayern KapitalBIBioGeneration VenturesCACanaan PartnersCOcoparion+2 more

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

RCRenato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsBIBioGeneration VenturesPUPureos BioventuresSESeventure PartnersJOJohnson & Johnson Innovation – JJDCBOBOMCUCurie Capital+1 more

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMZMai-Britt Zocca(CEO)in

Co-investorsMOMonograph Capital PartnersSOSofinnova Partners

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsFOForesite CapitalLOLongwood FundNONorwest Venture PartnersPIPivotal Life SciencesRIRiverVest Venture PartnersYSYsios Capital+4 more

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)GGGeoff Gilmartin(Chief Medical Officer)EHEric Hu(Chief Business Officer)

Co-investorsNONovo HoldingsSOSofinnova VenturesSASanofi Ventures

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical DevicesBrisbane, US

JMJordi Mata-Fink(Chief Executive Officer, Co-Founder)inRTRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)inJordi Mata-Fink, Ph.D.(Chief Executive Officer, Co-Founder)Raman Talwar, M.S.(Chief Technology Officer, Co-Founder)Pat Sharp, Ph.D.(Scientific Founder)

Co-investorsVEVersant VenturesANAndreessen HorowitzARARCH Venture PartnersFEFelicis VenturesGVGV (Google Ventures)

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

PLPatrick Loustau(President and Chief Executive Officer)in

Co-investorsNONovartis Venture FundSASanofi VenturesVEVersant Ventures

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)CKChrister Köhler(Founding Director)inKees Been(Chief Executive Officer)inJWJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYSYsios CapitalNONovartis Venture FundSUSunstone Capital

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)MCMark Coles(Founder)inSRSoumya Raychaudhuri(Founder)DADavid A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in

Co-investorsGVGV (Google Ventures)SVSV Health InvestorsJOJohnson & Johnson Innovation – JJDCNONorthpond VenturesJJJJDC

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)inKUKaren Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRERemiges Ventures, Inc.VEVesalius Biocapital Partners

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureBIBiotechnology Value FundLILightspeed Venture PartnersREResearch Corporation TechnologiesTCTCG Crossover

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

MSMoin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSOSofinnova PartnersGIGilde HealthcareADAdvent Life SciencesBRBritish Patient Capital

SOLASTA Bio develops bio-based crop protection products as alternatives to conventional agricultural chemicals, serving the agrifood and farming sector.

AgTechBiotechCleantechClimate Tech

SDShireen Davies(Co-founder & Chief Executive Officer)inJulian Dow(Co-founder & Chief Scientific Officer)Paula Pinto(Chief Strategy Officer)David Armour(Chief Financial Officer)Daphne Preuss(Chief Business Officer)Rob Wylie(Chair)

Co-investorsCACavallo VenturesRURubio Impact VenturesSCScottish EnterpriseTHThe Yield Lab EuropeCACarbonFUFuture Planet Capital+2 more

Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers.

BiotechHealthtechBoston, US

DFDavid Feltquate(Chief Medical Officer)inMaiken Keson-Brookes(Chief Operating Officer & General Counsel)CAROLINE LOEW(Executive Officer, Director, Promoter)Caroline J. Loew(President & Chief Executive Officer)

BoardALANDREW LEVIN(Director)JGJULIE GRANT(Director)in

Co-investorsRARA CapitalCACanaan Partners

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

RBRay Barlow(Chief Executive Officer)in

Co-investorsHEHealthCapBIBioqube VenturesGIGimvMEMedicxiRERed Tree Venture

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

TSThorsten Stafforst(Chairman of the Board of Directors)inKEKris ElveruminTBTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+N+ND CapitalARARCH Venture PartnersVEVenrockFAFast Track InitiativeLILifelinkNENextech Invest+3 more

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Board seatNLNanna Lüneborg· per SEC Form D

Co-investorsFIFinchley Healthcare VenturesPFPfizer Venture InvestmentsRARA CapitalSOSofinnova VenturesVIVida VenturesALAlexandria

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)in

Board seatGMGeert-Jan Mulder· per SEC Form D

Co-investorsARArcus VenturesNGNGN Capital

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seatMBMarco Boorsma· per SEC Form D

Co-investorsPAPappas CapitalAMAmplitude Venture CapitalDODomain AssociatesRTRTW Investments L.P.

Co-investorsNENeva Sgr.SOSofinnova PartnersXGXGEN VentureATAtlas VentureLOLongwood Fund

Abiomed develops Impella heart pumps, minimally-invasive cardiovascular devices used to treat high-risk PCI, cardiogenic shock, and right heart failure.

HealthtechMedical Devices

David Lederman(Founder)

Acadia is a biopharmaceutical company developing therapies for underserved neurological disorders and rare diseases.

BiotechHealthtech

Co-investorsNENew Enterprise Associates (NEA)

Agendia develops genomic technology and diagnostic tests for breast cancer patients.

AI & Machine LearningBiotechDigital HealthMedical DevicesIrvine, US

LVLaura van 't Veer(Co-founder)inRBRené Bernards(Co-founder)inProf. Laura van 't Veer, PhD(Chief Research Officer, Co-founder)PDProf. Dr. René Bernards, PhD(Co-Founder and Scientific Advisor)MRMark R. Straley(CEO)in

Co-investorsKOKorysGIGilde Healthcare

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesRARA CapitalSOSofinnova VenturesATAtlas Venture

Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).

Co-investorsANAndera PartnersBIBioMedPartnersDEDelos CapitalEMEMBL VenturesXEXeraya Capital

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

JCJohn Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

BoardNWNicholas Williams(Director)MSMoncef Slaoui(Director)JEJon Edwards(Director)in

Co-investorsGRGRA VentureMEMedicxiPIPitangoSASanofi Ventures

AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease.

BiotechHealthtech

Co-investorsANAndera PartnersKUKurma PartnersYSYsios Capital

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

LMLouise Modis(Chief Executive Officer)inMPMartin Pass(Chief Development Officer)inGBGiles Brown(Executive VP Drug Discovery)in

Co-investorsADAdvent Life SciencesNONovartis Venture FundSVSV Health InvestorsDEDementia Discovery FundEUEuropean Investment FundGIGilde Healthcare+2 more

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

TThaminda(Chief Business Officer)inLPLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNONovartis Venture FundPFPfizer Venture InvestmentsPOPontifax Venture Capital

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPEPebblebedANAndera PartnersBGBGVFOFountain Healthcare PartnersHTHTGFPMPMV+2 more

The company develops therapies for people with severe autoimmune diseases.

BiotechHealthtechMedical Devices

Co-investorsAVAvoro Capital AdvisorsBIBioGeneration VenturesHBHBM Healthcare InvestmentsMPMPM BioImpactPMPMVSESeventure Partners+2 more

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsARARCH Venture PartnersEAEaston CapitalRARA CapitalSASanofi VenturesTHThink+ Ventures Management, LlcWAWakestream Ventures+1 more

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

TMTravis Murdoch, M.D.(Chief Executive Officer and Board Director)in

Co-investorsANAndreessen HorowitzFRFrazier Life SciencesOROrbiMed

Completed patient enrollment in its Phase 2 AURORA trial.

Co-investorsP5P53 InvestSASarsia Management ASINInvestinor

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.

BiotechHealthtechMedical Devices

Azim Surani(Co-founder)

Co-investorsAVAvego BioScience CapitalFUFuture Planet CapitalHBHBM Healthcare InvestmentsHBHBM PartnersRARA CapitalSOSofinnova Partners+3 more

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

RHRafiq Hasan(CEO and Managing Director)inMAMuhammad Ali Memon(Chief Medical Officer)in

Co-investorsBIBioGeneration VenturesCACambridge Innovation CapitalGIGimvHAHadean VenturesSESeroba Life SciencesBGBGV+2 more

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

PRPierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMDMarie De Vulder(Chief Legal Officer Co-founder)inGPGuy Peeters(Chief Financial Officer Co-founder)inJGJohn-Paul Gallivan(Head of Development Co-founder)inFKFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsFIFinchley Healthcare VenturesLOLongwood FundLULuma GroupSOSofinnova VenturesBABAM ElevateNONovo Holdings+2 more

Curetis develops molecular diagnostic systems for detecting pathogens and antimicrobial resistance markers in severe infections.

BiotechHealthtechMedical Devices

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

JFJohn Ford(Co-founder)inMGMartin Gosling(Founder)in

Co-investorsEPEpidarex CapitalNONovartis Venture FundVEVersant VenturesIPIP GroupPAPanakes Partners

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsADAdvent Life SciencesAIAisling CapitalAMAMR Action FundASAstellas Venture Management LLCBRBrace PharmaSOSofinnova Partners+4 more

Gate.io is a cryptocurrency exchange platform offering perpetual futures contracts, options, CFDs, spot trading, and tokenized stocks.

AI & Machine LearningCrypto & Web3Fintech

Co-investorsTOTokoin

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

FKFabien Koutchekian(Founder)inDRDali Rashid(Founder)inDr. Dali Rashid(Founder)

Co-investorsCACarbonDEDeepTech & Climate FondsENEntrepreneur FirstHEHEC Paris IncubatorLOLowercarbon CapitalSTSTATION F+7 more

Co-investorsFOFountain Healthcare PartnersLOLongitude Capital

Inthera Bioscience AG is a biotech company with expertise spanning target discovery, drug discovery, medicinal chemistry, preclinical and toxicology work, and early clinical development.

BiotechDeep Tech

Mark Krul(Board of Directors)inKarl Rothweiler(Board of Directors)Martin Bonde(Board of Directors)

Co-investorsM M Ventures

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAMAmorChemGEGenesys CapitalJDJDRF T1D FundNENew Enterprise Associates (NEA)TATarnagulla VenturesADadMare BioInnovations+2 more

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

DRDavid Reynolds(Co-founder & CEO)inCBCaroline Benn(Co-founder & CSO)in

Co-investorsDEDementia Discovery FundNONovartis Venture FundSVSV Health Investors

MapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.

AI & Machine LearningBiotechHealthtechMedical Devices

CKChristopher Kroeger, M.D.(Chief Executive Officer, Founder, Board Member)Karl Deisseroth, M.D., Ph.D.(Founder, Scientific Advisory Board)Robert Malenka, M.D., Ph.D.(Founder, Board Member, Scientific Advisory Board)Christopher Kroeger(Founder)Karl Deisseroth(Founder)Karoly Nikolich(Founder)

Co-investorsAVAvego BioScience CapitalPIPivotal Life Sciences

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsACAccess BiotechnologyATAtlas VentureNENextech InvestACAccess IndustriesRARA Capital

HealthtechTewksbury, US

Lisa Mastromattei(Executive Officer)Lisa Wipperman Heine(Executive Officer)Sophia Wong(Executive Officer)Richard P. Geoffrion(Executive Officer, Director)

BoardMartien Van Osch(Director)Daniel Cole(Director)

Co-investors41415 CapitalQIQiming Venture PartnersSASaints CapitalXEXeraya CapitalOXOxford Bioscience Partners

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.

BiotechDigital HealthHealthtechMedical Devices

Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)

BoardDavid White(Sleep Medicine Advisor)

Co-investorsBRBroadview VenturesNONorwest Venture PartnersPIPivotal Life SciencesSUSupermoon CapitalHTHTGFINInkef

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAGAgate Medical Investments LPSCSCP Vitalife PartnersGVGV (Google Ventures)NONorthpond VenturesSVSV Health Investors

Co-investorsADAdvent Life SciencesFOFountain Healthcare PartnersOROrbiMedCOColumbus Venture PartnersRERedwood Ventures

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsBABain Capital Life SciencesBIBioGeneration VenturesEQEQT Life SciencesFRFrazier Life Sciences

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

ILIlise Lombardo(Chief Executive Officer)inVKVolker Knappertz(Executive Vice President of Research & Development)inMSMichael Samar(Chief Financial Officer)inRLRob Lasser(Chief Medical Officer)in

Co-investorsBIBioMedPartnersJEJeito CapitalRORoche Venture FundSOSofinnova PartnersEQEQTEQEQT Life Sciences+2 more

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNENew Science VenturesVEvenBio PartnersYSYsios CapitalBGBGVNONovo HoldingsBIBioGeneration Ventures+1 more

NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.

FoodTech

GSGiuseppe Scionti(Founder)in

Co-investorsAUAurum Venture PartnersCACarbonJOJoyance PartnersSOSofinnova PartnersUNUnovis Asset ManagementVUVU Venture Partners+1 more

Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.

BiotechDeep Tech

DUDavid Urech(Founder)in

Co-investorsEIEisai Innovation, Inc.HBHBM Healthcare InvestmentsHBHBM PartnersBIBiotechnology Value FundBLBlackRockNONovo Holdings+1 more

Oncology Ventures is a cancer-focused venture capital fund that invests in healthcare technology startups related to oncology care.

AI & Machine LearningBiotechDigital HealthHealthtech

BFBen Freeberg(Founder, Managing Partner)inJay Freeberg(Chief Financial Officer)

Co-investorsSASandwich CapitalALAlleyCorpCACanaan PartnersCOConcord Health PartnersCVCVS Health VenturesFOForesite Capital+5 more

Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsNENew Enterprise Associates (NEA)LILilly VenturesNONovo Holdings

PACT develops earth-positive biomaterials for the fashion industry, scaling them up for supply to partner brands.

BiotechCircular EconomyClimate TechNew MaterialsLondon, GB

YDYudi Ding(Founder & CEO)inNiels Ramay(Founder)in

Co-investorsCACarbonDADAO JonesENEntrepreneur FirstHOHoxton VenturesHVHV CapitalKIKIN Group+2 more

Co-investorsBIBioMedPartnersHEHealthCapINInkefPOPontifax Venture CapitalV-V-Bio Ventures

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsCACardinal PartnersM M VenturesSESeroba Life SciencesSUSunstone CapitalYSYsios Capital

Prilenia is a biotechnology company developing treatments for neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS).

BiotechHealthtechMedical Devices

Co-investorsALALS Investment FundSVSV Health InvestorsAMAmplitude Venture Capital

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

DHDmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)MTMarc-Olivier Turgeon(Director)in

BoardARAleks Radovic-Moreno(Director)inDan Janney(Director)

Co-investorsALAlta PartnersDODolby Family VenturesLOLongwood FundMIMission BiocapitalSEService Provider Capital

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)GMGeert-Jan Mulder(Director)inJFJohn Friedman(Director)inHarold R. Werner(Director)

Co-investorsEAEaston CapitalSOSofinnova VenturesEAEaston Capital Investment Group

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

PRPablo Rojas(Founder)inRafael Casabianca

Co-investorsNONovartis Venture FundY Y CombinatorDIDigitalis VenturesDRDroia VenturesGLGlilot Capital PartnersGLGlobal Founders Capital+7 more

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

BJBrent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDRDroia VenturesNONovartis Venture FundDIDigitalis VenturesLILightspeed Venture PartnersMPMPM BioImpactVIVida Ventures+1 more

Developing safe, long-lasting gene therapy treatments in a redosable, non-viral format.

Louis Breton(Founder)in

Co-investorsHEHealthCapOROrbiMed

Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.

BiotechDeep Tech

RDRajesh Devraj(President and Chief Executive Officer)inRHRobert Hughes(Chief Scientific Officer)inPBPol Boudes(Chief Medical Officer)

Co-investorsATAtlas VentureDCDC Investment PartnersLOLongwood Fund

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFRFrazier Life SciencesLILifeArc VenturesOXOxford Science EnterprisesWEWellington ManagementEQEQT Life SciencesMOMonograph Capital Partners+1 more

Seamless Therapeutics develops gene-editing therapies using programmable recombinase technology to make large, precise DNA deletions or insertions and correct the genetic causes of disease.

BiotechMedical DevicesDresden, DE

Anne-Kristin Heninger(Co-founder, Head of Operations & Managing Director (Germany))Felix Lansing(Scientific Co-founder & Chief Technology Officer)Albert Seymour(President, CEO & Managing Director)inDeborah Kinch(Head of R&D, Regulatory/Quality, CMC/Technical Operations)

Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.

Biotech

Co-investorsCACatalio Capital Management, LPRARA CapitalNONovo Holdings

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.

BiotechHealthtechMedical DevicesPortland, US

RJRobert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)

BoardJRJonathan Root(Director)inNONiall O'Donnell(Director)inZSZach Scheiner(Director)inKVKlaus Veitinger(Director)in

Co-investorsOROrbiMedRARA CapitalRIRiverVest Venture PartnersUSUS Venture Partners

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.

BiotechMedical Devices

TETony Estrada(President & Chief Executive Officer; co-founder)in

Co-investorsARARCH Venture PartnersF-F-Prime CapitalBABain Capital Life SciencesDIDigitalis VenturesMUMubadala Capital

Tessellate Bio is a biotech company researching synthetic lethal interactions beyond Homologous Recombination Deficiency (HRD) to build a pipeline of first-in-class precision medicines.

BiotechHealthtech

Co-investorsBIBioGeneration VenturesBGBGV

Tropic is a procurement platform that gives finance and procurement teams pricing intelligence, negotiation playbooks, and expert support to reduce spend on SaaS and AI software.

AI & Machine LearningFintechSaaSNew York City, US

JEJustin Etkin(Founder)inDCDavid Campbell(Founder)in

Co-investorsCACanaan PartnersFOFOG VenturesFOFounder CollectiveINInsight PartnersSHShine CapitalGEGenoa Ventures

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

MKMatthew Kapustain

Co-investorsADAdvent Life SciencesALALS Investment FundFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSRIRidgeback Capital

Verdiva Bio is a biotechnology company focused on drug development.

BiotechHealthtech

JHJane Hughes(Chief Scientific Officer)inKFKhurem Farooq(Founder)in

Co-investorsGEGeneral AtlanticOROrbiMedRARA Capital

Kaleido, a lightweight modular precision-dosing insulin pump.

Co-investorsINInkefINInnovation IndustriesEQEQT Life SciencesINInvest-NLROROM Utrecht Region